I was lucky enough to pick up 10k shares of nstk on thursday. As far as the deal goes I think 5 million for a drug that has only completed phase 1 trials and 341 million in milestone payments is not bad. Nstk will manufactor the drug and also get a cut of sales. Merck is certainly a nice partner. My guess is they where shooting for 20% of sales but settle for less. Also all drug development costs are Mercks. Compare this to the deal genr received for il-9.
As for the nstk poster dew mention, I have talked with him in the past and still stay in touch with him even though he can no longer talk about nstk with me. Nice guy. Smart guy. He has been on wall street for years and I think he will protect my investment. I wouldn't have any problems with Dew being put on Genrs board. If he was I bet we would find out who the hell was making squalamine and how much of it they can produce.
I invested in nstk as a short term play with plans to sell at the start of phase II PYY trials.
Nstks last conf call mentioned they where in talks with 6 different co's for drug deals. I guess thats 5 now. I think a deal for calcitonin, a drug that will likely get approval on early next year, will happen soon. Roughly 250 million dollar. Existing drugs are injection, ouch, and nasal delivery. The nasal delivery drug is good but they do have nasal problems, bleeding,etc.. in roughly 15-20% of patients. The prescription writer in my home would choose nstk drug first because of the low risk profile.
I plan on holding nstk longer now pending other news, deals, upgrades. I also think this does validate nstk's tight junction delivery. If nothing happens I will exit nstk before pyy phase II results are announced.
IMHO, Randy
Market Data 
Markets 
AI
